Supporting the next generation of therapeutic vaccines
Vaccine adjuvants are used to enhance immune response to an antigen, improving the overall efficacy of the vaccine and increasing protection against the target disease.
Croda is the leading independent supplier of vaccine adjuvants with unrivalled breadth across aluminium, saponin and lipid-based adjuvants. In addition to traditional prophylactic (preventative) vaccines, our technology is enabling the next generation of therapeutic vaccines, used to combat an already contracted disease. These are typically higher value, requiring more advanced adjuvant systems. One of Croda’s adjuvant systems is included in a personalised immunotherapy drug candidate, currently in phase II clinical trials. The vaccine, in combination with an inhibitor treatment, targets metastatic melanoma, a disease occurring when cancerous cells from the primary tumour spread, starting a new tumour elsewhere in the body.